Skip to main content

Featured

AIR MILES Is Gone. Here's What Actually Earns You Travel Now

  If you've been holding onto a Air Miles card waiting to redeem for a flight, the program you signed up for doesn't exist anymore — and the cards that replaced it aren't the best game in town. If you searched "best AIR MILES credit card" and landed here, there's something you need to know first: there is no such thing anymore. AIR MILES, the loyalty program that's been part of Canadian wallets since 1992, officially became BMO Blue Rewards on June 2, 2026. BMO had already stopped issuing new AIR MILES cards back in January, and every collector's Miles converted automatically into Blue Points at a rate of roughly 1 Air Mile to 15.79 Blue Points — no action needed, no lost value. That's good news if you're a longtime collector sitting on a pile of Miles. It's less good news if you were hoping to earn free flights that way going forward, because Blue Rewards was built to compete with PC Optimum and Scene+ — grocery, gas, and everyday spendi...
Post a Comment
Read more

article

Labels

U.S. Drug Tariffs: A Looming Crisis for Global Supply Chains


The U.S. government's decision to impose tariffs on pharmaceutical imports has sent shockwaves through the healthcare industry, raising concerns about potential drug shortages and skyrocketing costs. Industry leaders warn that these tariffs could disrupt critical supply chains, affecting the availability of essential medications and medical devices.

Johnson & Johnson CEO Joaquin Duato has voiced concerns over the impact of these tariffs, advocating for tax incentives instead of trade barriers to support domestic drug manufacturing Warns Tariffs Could Disrupt U.S. Drug Supply Chains](https://www.theglobeandmail.com/investing/markets/stocks/LLY-N/pressreleases/31903548/jj-ceo-jnj-warns-tariffs-could-disrupt-us-drug-supply-chains/). Meanwhile, a recent survey indicates that healthcare executives anticipate significant price hikes, with some predicting an 18% increase in medical equipment costs and a 33% rise in critical device prices.

The American Hospital Association has urged the administration to reconsider these tariffs, emphasizing the reliance of U.S. healthcare providers on international sources for life-saving drugs and supplies. Experts caution that while the tariffs aim to boost domestic production, the transition could take years, leaving patients vulnerable to shortages and inflated prices.

As pharmaceutical companies scramble to adjust their supply chains, the industry faces an uncertain future. Whether these tariffs will achieve their intended goal or exacerbate existing challenges remains to be seen. Policymakers must weigh the long-term consequences carefully to ensure that patient care and affordability are not compromised.

Labels:

Comments

Post a Comment